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Two-year follow-up results of the SPACE study
Thomas L. Forbes, MD, London, Ontario, CanadaThe 2-year results of the Stent-protected Percutaneous
Angioplasty vs Endarterectomy of Symptomatic Carotid
Artery Stenosis (SPACE) study were recently presented at
the 2009 International Stroke Conference of the American
Heart Association (San Diego, Calif, Feb 18-20, 2009).1
The SPACE study was a multinational randomized
controlled trial comparing carotid artery stenting (CAS)
with endarterectomy (CEA) in the treatment of patients
with symptomatic carotid stenoses. The primary end point
was the composite of 30-day rate of stroke or death and was
analyzed using a noninferiority test (threshold, 2.5%). The
study failed to prove noninferiority for the primary end
point in the 1214 randomized patients (absolute differ-
ence, 0.47; 95% confidence interval [CI], –2.41 to 3.35;
P  .09).
In this report, 2-year follow-up information was com-
plete in 88.9% of patients. The 2-year Kaplan-Meier esti-
mates of stroke or death did not differ between the CAS
(9.5%) and CEA (8.8%) groups (hazard ratio, 1.10; 95%
CI, 0.75-1.61). Recurrent stenosis (70%) was signifi-
cantly more frequent after CAS (hazard ratio, 2.23; P 
.0004). Patient age was observed to be the only character-
istic predictive of periprocedural risk after CAS (P  .008)
but not CEA (P  .45). Patients aged 68 years had a
nonsignificant trend of fewer strokes and deaths after CAS
(8.8% for CEA vs 4.8% for CAS, P  .056). Those aged
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(8.2% for CEA vs 13.4% for CAS, P  .039).
Initially, SPACE failed to show noninferiority of CAS
compared with CEA. The rates of stroke and death after 2
years did not differ between the CAS and CEA groups,
despite an increased rate of restenosis in the CAS group.
COMMENTARY
The initial SPACE report failed to show noninferiority
of stenting compared with endarterectomy for symptom-
atic stenoses, considering periprocedural (30 days) rates
of stroke and death.2 In this update of results at 2 years, the
combined rate of stroke and death continues not to differ
between the two treatments. The increased restenosis rate
in the stented patients is significant, although the longer-
term effects of this have yet to be determined. Subgroup
analysis suggests that older patients (68 years) are best
treated with surgery, but the overall influence of patient age
is unclear.
As a result of this study, and others, it is apparent that
the role of stenting in average-risk patients remains unclear,
with unproven advantages.
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